Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.

http://www.wikidata.org/entity/Q40506711

about

Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.Gemcitabine for the treatment of advanced nonsmall cell lung cancer Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.PharmGKB summary: gemcitabine pathway Hippo pathway mediates resistance to cytotoxic drugs.Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.Clinical pharmacology and pharmacogenetics of gemcitabine.The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone Personalized therapy for pancreatic cancer: Myth or reality in 2010?Gemcitabine in metastatic breast cancer.Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity.Role of gemcitabine in cancer therapy.In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.Pancreatic cancer: why is it so hard to treat?Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.Human nucleoside transporters: biomarkers for response to nucleoside drugs.Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.Molecular predictors of prognosis in lung cancer.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Pharmacogenomics in the treatment of lung cancer: an update.Effect of Hypoxanthine on Functional Activity of Nucleoside Transporters ENT1 and ENT2 in Caco-2 Polar Epithelial Intestinal Cells.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding.Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells.

P2860

Q28308112-C1F6CEF1-5281-4190-9AA2-D031F72E6DE5 Q28396304-547158F5-0F11-4868-A137-DFCAA93EB96D Q28481440-AD05A465-F18E-4163-8F9F-B554E76D5B68 Q33245149-C933DDBA-F847-4DBA-B995-92AA58E415FC Q33336057-EEC13025-3E3D-41C1-BBA0-55C07FF09646 Q33575608-45E83E88-E797-48F4-A0CD-C3107F14F83E Q33915997-27DA0542-1E09-475F-B627-EE254C9F5ECA Q34254837-35746F89-CF8F-4C44-8268-EC9978BB927E Q34435450-C633342B-9104-4DAA-BF8B-7438DCCD3F9A Q34555337-2181B2D8-9F1D-4DE8-B6EA-7CB493A40D47 Q34609029-7E0B91B2-ADDF-4806-92DD-B3436AEDC69D Q34985979-DFA88759-7E9F-4707-A8DC-FE6BE2AF3C2E Q35194201-2CDC6B4A-7850-4D7A-8DAC-B0D24EF4D689 Q35945507-386EC0E8-06E2-4432-8257-08DCB7299DD8 Q36097060-283FC3B7-E4D2-4EA9-B895-36924B933DA8 Q36185611-D8F4F95E-AFFD-4D90-8E4A-ABD7766AEC2B Q36298003-CF8CD086-2A0B-4214-AB4A-F52844F58A24 Q36342657-C8855A8D-27AE-4F66-8B1C-679DFC1BF809 Q36378036-E73396BE-373C-488C-83FB-E30151C4331F Q36429373-A472EF66-58E1-4822-8740-3C92BE230A1E Q36612195-BC009136-F1D8-4631-8874-9D8C0B0C40B7 Q36886497-4D1C2E6A-48CE-467E-8705-F581AE0057F7 Q36924856-F392775D-917D-44DB-A062-284096377629 Q37249378-A1512B4F-B3EE-4169-AB83-E8B5505A2A0D Q37688480-2B35A654-2085-43D5-997C-804BAE354472 Q37698437-ED807203-E3E4-459D-846C-A19E8E64F2F2 Q37714232-03BB18A0-983F-4B65-BD6C-8DFECFC6A681 Q37913090-4B0DD1FF-1926-4816-9C45-C4F4952561D0 Q38030053-BE2854BB-1C63-42F6-9AE9-596C028EC887 Q38075827-572624DA-03CB-4C64-B769-44EA852F6147 Q38312045-D84139DB-1C9C-43B2-90A9-5DFA797FE665 Q38596926-12144465-599A-43A9-825E-5C598F262CB1 Q38817729-68E647CF-E25D-44CD-AFF0-5666E1D2F24B Q38922208-0CA9D08F-F7FD-4B72-B6CD-5249C36CF94A Q39280587-687C58AA-7824-45F0-BBD9-E3140AA82817 Q39379544-D52584A3-934D-423E-8CEC-29AC0CBBFBF3 Q39776948-625A9D91-55A7-49DF-ABF0-9355889B3AAA Q39892650-1E68BDCA-6C63-498B-BAF9-E8E691B6B01E Q39965228-8024BC9E-83B0-4026-BC04-41D126509D9B Q40298723-59C15109-9DD1-4BBC-9C6B-42417B8C664C

P2860

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.

http://www.wikidata.org/entity/Q40506711

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Determinants of sensitivity an ...... in non-small cell lung cancer.

@en

type

label

Determinants of sensitivity an ...... in non-small cell lung cancer.

@en

prefLabel

Determinants of sensitivity an ...... in non-small cell lung cancer.

@en

P1433

Q40506711-66EA19C1-E770-4440-AB3F-081F7947F2CA

P1476

Q40506711-38B5E158-C8B3-47C1-B5D2-9A182EE14CB9

P2093

Q40506711-4557FBFF-6869-4813-BD8B-741F87F1E4BC

Q40506711-4F14BE7B-0B9D-47CC-B41E-3652562B2872

Q40506711-5A3E8620-B6E1-4F02-BE7D-F88B629444B1

Q40506711-9A53F0F1-4893-48AD-8D67-52A329B7F16A

Q40506711-9D76B347-7F2B-4CC5-91F4-AF8B94833A1F

Q40506711-DAB63979-9EB9-4EC7-8417-5F90522417A2

P2860

Q40506711-0E37F3EC-007C-4F2D-8DCA-2F84F778F237

Q40506711-2A4D6038-20C9-4E76-A97A-E84E7933FA2F

Q40506711-2C78532E-50C1-42F8-BDDB-EE9D29DD77D9

Q40506711-3498C293-9297-48CC-A586-EB0DAC1E39CE

Q40506711-448B09ED-680F-4935-A51F-24531BD65D06

Q40506711-4C7F41F0-28D3-43B3-B4DB-B4D3C1D2A6F0

Q40506711-56D01DEC-E8B2-48C5-B16A-79C1EAB6AD81

Q40506711-6F5A18A5-AA00-42FA-A92A-897F42EDE414

Q40506711-787822CA-96F9-46EC-8ADC-78435B304539

Q40506711-7A2B7F5F-DC94-4E44-848C-B8B79D217ADA

P304

Q40506711-E1260154-0D1F-4B67-8ED2-68803192CADF

P31

Q40506711-929641F3-6F3E-4398-9D78-65A3F6519C40

P356

Q40506711-9ADD3128-18B6-471F-A824-C64415FF92A1

P433

Q40506711-53FB57A1-F90A-4C0B-A2FD-A140F2BED133

P478

Q40506711-C4114AFA-30F6-47F5-9893-85B81D8AD1F2

P577

Q40506711-D59E3D1D-4D29-4B16-85AC-97173B471E8E

P5875

Q40506711-4A794FE0-E5AD-4169-9F9D-ADA8790357CE

P698

Q40506711-44A52D37-CD45-4195-BD8D-5104B9A03B89

P356

J.1349-7006.2004.TB03257.X

P1433

P1476

Determinants of sensitivity an ...... in non-small cell lung cancer.

@en

P2093

Hiroyoshi Maeda

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Achiwa

http://www.w3.org/2001/XMLSchema#string

Ryuzo Ueda

http://www.w3.org/2001/XMLSchema#string

Shigeki Sato

http://www.w3.org/2001/XMLSchema#string

Takashi Niimi

http://www.w3.org/2001/XMLSchema#string

Tetsuya Oguri

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).

Nucleoside transporters: molecular biology and implications for therapeutic development.

Potential mechanisms of resistance to cytarabine in AML patients.

Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.

Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content.

Nucleoside transport in normal and neoplastic cells.

In vitro leukemia cell models of Ara-C resistance.

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.

P304

753-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.2004.TB03257.X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8243360

http://www.w3.org/2001/XMLSchema#string

P698

15471562

http://www.w3.org/2001/XMLSchema#string